BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Filspari (sparsentan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Filspari (sparsentan)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07224776-10808@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Filspari (sparsentan): Phase 1 readout est. (NCT07224776)
DESCRIPTION:Filspari (sparsentan)\, phase 1.\nStudy: Sparsentan for the Tre
 atment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria\nEstimat
 ed primary completion: 1 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sparsentan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07224776
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219121-10808@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Filspari (sparsentan): Phase 4 readout est. (NCT07219121)
DESCRIPTION:Filspari (sparsentan)\, phase 4\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Sparsentan in Posttransplant Immunoglobulin A Nephropathy o
 r Focal Segmental Glomerulosclerosis\nEstimated primary completion: March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07219121
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05003986-10808@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT05003986)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Study of Sparsentan Treatment in Pediatrics With Proteinuri
 c Glomerular Diseases\nEstimated primary completion: 12 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05003986
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663204-10808@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT04663204)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, IgA Nephropathy.\nStudy: A St
 udy of the Safety and Activity of Sparsentan for the Treatment of Patients
  With Immunoglobulin A Nephropathy\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sparsentan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0466
 3204
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
